Remove 2024 Remove Quality of Life Remove Transplant
article thumbnail

Ochsner Children’s Hospital Advocates to Close the Gap in Pediatric Heart Care

DAIC

Getty Images milla1cf Wed, 02/21/2024 - 19:10 February 21, 2024 — Ochsner Children's Hospital , ranked among the top hospitals in the nation for pediatric cardiology and congenital heart surgery, is raising awareness of the need for more pediatric-specific heart devices. Yet, research and innovation in this field has not kept pace.

article thumbnail

CVRx Announces Availability of Additional Data Supporting Long-term Benefits of Barostim

DAIC

milla1cf Tue, 04/16/2024 - 12:35 April 16, 2024 — CVRx, Inc., Dr. JoAnn Lindenfeld of Vanderbilt University presented analysis showing that patients with Barostim + GDMT had sustained and significant improvements in quality-of-life scores (MLWHF and EQ-5D) and many subdomains of these scores (e.g.,

article thumbnail

BioCardia Announces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study

DAIC

Getty Images milla1cf Wed, 03/13/2024 - 16:49 March 13, 2024 — BioCardia, Inc. , The CMS coverage approval is supported by the scientific rigor of the protocol design and the results from the interim data from the CardiAMP Heart Failure Trial recently presented at the Technology and Heart Failure Therapeutics 2024 annual meeting.

CMS 111
article thumbnail

The Texas Heart Institute Collaborates on Multi-institutional DOD Grant to Develop Novel Left Ventricular Assist Device

DAIC

Patients with heart failure often experience reduced mobility, quality of life and ability to work; the disease also represents a significant public health care burden. Cardiac transplantation, the only option for many patients, is severely restricted by the limited availability of donor hearts.

article thumbnail

V-Wave to Present Late-Breaking Data from Pivotal RELIEVE-HF Study at American College of Cardiology Annual Scientific Session and Expo

DAIC

milla1cf Fri, 03/29/2024 - 08:08 March 29, 2024 — V-Wave announced it will present late-breaking data from its RELIEVE-HF pivotal trial at the American College of Cardiology 's ( ACC ) Annual Scientific Session & Expo taking place April 6-8 in Atlanta. and worldwide," said Neal Eigler, M.D. , CEO of V-Wave. healthcare system.

article thumbnail

Impact of Interatrial Shunt May Vary by Heart Failure Type

DAIC

Surprisingly, a marked improvement in quality of life as measured with KCCQ was observed across all groups—including those who received a placebo procedure, both with HFrEF and HFpEF—suggesting that the metric may not be a reliable indicator for quality-of-life outcomes in this context, Stone said.

article thumbnail

RELIEVE-HF Trial Outcomes Reported at ACC.24 Find Impact of Interatrial Shunt May Vary by Heart Failure Type

DAIC

Surprisingly, a marked improvement in quality of life as measured with KCCQ was observed across all groups—including those who received a placebo procedure, both with HFrEF and HFpEF—suggesting that the metric may not be a reliable indicator for quality-of-life outcomes in this context, Stone said. 24, in Atlanta, GA.